Literature DB >> 6410450

Absence of central effects in man of the benzodiazepine antagonist Ro 15-1788.

A Darragh, R Lambe, C O'Boyle, M Kenny, I Brick.   

Abstract

The benzodiazepines are typified by a profile of side effects which includes drowsiness, ataxia and incoordination. Ro 15-1788, an imidazodiazepine derivative, exhibits marked antagonism of the behavioural and biochemical effects of the benzodiazepines in animals and man. It is devoid of any behavioural activity in animals, except at very high doses. In the present study the effects of single rising oral doses of Ro 15-1788 on cognitive, psychomotor and subjective function in man have been assessed using a battery of psychometric tests designed to identify the sedative action of the benzodiazepines. At all doses up to 600 mg, Ro 15-1788 demonstrated none of the classical behavioural effects of the benzodiazepines.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6410450     DOI: 10.1007/BF00427969

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  18 in total

1.  Critical flicker frequency (CFF) and psychotropic drugs in normal human subjects-a review.

Authors:  J M Smith; H Misiak
Journal:  Psychopharmacologia       Date:  1976-05-28

2.  Benzodiazepine receptors in rat brain.

Authors:  R F Squires; C Brastrup
Journal:  Nature       Date:  1977-04-21       Impact factor: 49.962

Review 3.  Molecular mechanisms in the receptor action of benzodiazepines.

Authors:  E Costa; A Guidotti
Journal:  Annu Rev Pharmacol Toxicol       Date:  1979       Impact factor: 13.820

4.  Investigation in man of the efficacy of a benzodiazepine antagonist, Ro 15-1788.

Authors:  A Darragh; R Lambe; M Scully; I Brick; C O'Boyle; W W Downe
Journal:  Lancet       Date:  1981-07-04       Impact factor: 79.321

5.  Autoradiographic localization of benzodiazepine receptors in immunocytochemically identified gamma-aminobutyrergic synapses.

Authors:  H Möhler; J G Richards; J Y Wu
Journal:  Proc Natl Acad Sci U S A       Date:  1981-03       Impact factor: 11.205

6.  Agonist and antagonist benzodiazepine receptor interaction in vitro.

Authors:  H Möhler; J G Richards
Journal:  Nature       Date:  1981-12-24       Impact factor: 49.962

7.  RO 15-1788 antagonises the central effects of diazepam in man without altering diazepam bioavailability.

Authors:  A Darragh; R Lambe; M Kenny; I Brick; W Taaffe; C O'Boyle
Journal:  Br J Clin Pharmacol       Date:  1982-11       Impact factor: 4.335

8.  Interaction between effects of caffeine and lorazepam in performance tests and self-ratings.

Authors:  S E File; A J Bond; R G Lister
Journal:  J Clin Psychopharmacol       Date:  1982-04       Impact factor: 3.153

Review 9.  Receptors for the age of anxiety: pharmacology of the benzodiazepines.

Authors:  J F Tallman; S M Paul; P Skolnick; D W Gallager
Journal:  Science       Date:  1980-01-18       Impact factor: 47.728

10.  Selective antagonists of benzodiazepines.

Authors:  W Hunkeler; H Möhler; L Pieri; P Polc; E P Bonetti; R Cumin; R Schaffner; W Haefely
Journal:  Nature       Date:  1981-04-09       Impact factor: 49.962

View more
  15 in total

1.  The effects of the benzodiazepine antagonist Ro 15-1788 on psychophysiological performance and subjective measures in normal subjects.

Authors:  A Higgitt; M Lader; P Fonagy
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

Review 2.  Flumazenil. A reappraisal of its pharmacological properties and therapeutic efficacy as a benzodiazepine antagonist.

Authors:  R N Brogden; K L Goa
Journal:  Drugs       Date:  1991-12       Impact factor: 9.546

Review 3.  Flumazenil in dentistry.

Authors:  C Rodrigo
Journal:  Anesth Prog       Date:  1995

4.  Pharmacokinetics of the new benzodiazepine antagonist Ro 15-1788 in man following intravenous and oral administration.

Authors:  G Roncari; W H Ziegler; T W Guentert
Journal:  Br J Clin Pharmacol       Date:  1986-10       Impact factor: 4.335

Review 5.  Intrinsic actions of the benzodiazepine receptor antagonist Ro 15-1788.

Authors:  S E File; S Pellow
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

6.  Cerebral-activating (EEG) properties of two inverse agonists and of an antagonist at the benzodiazepine receptor in the rat.

Authors:  V Santucci; M Fournier; P Worms; P Keane; K Bizière
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1989-07       Impact factor: 3.000

7.  Benzodiazepine withdrawal: an unfinished story.

Authors:  H Ashton
Journal:  Br Med J (Clin Res Ed)       Date:  1984-04-14

8.  Flumazenil for the Treatment of Refractory Hypersomnolence: Clinical Experience with 153 Patients.

Authors:  Lynn Marie Trotti; Prabhjyot Saini; Catherine Koola; Vincent LaBarbera; Donald L Bliwise; David B Rye
Journal:  J Clin Sleep Med       Date:  2016-10-15       Impact factor: 4.062

9.  Plasma pharmacokinetics and metabolism of the benzodiazepine antagonist [11C] Ro 15-1788 (flumazenil) in baboon and human during positron emission tomography studies.

Authors:  D Debruyne; P Abadie; L Barre; F Albessard; M Moulin; E Zarifian; J C Baron
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1991 Apr-Jun       Impact factor: 2.441

10.  Behavioral effects of flumazenil in the social conflict test in mice.

Authors:  L Uhlírová; M Sustková-Fiserová; M Krsiak
Journal:  Psychopharmacology (Berl)       Date:  2003-09-05       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.